Insmed, Inc. (INSM) Business Profile

What it does

Insmed is a biopharmaceutical company that develops and sells medicines for serious diseases. Its commercial products treat respiratory conditions, while its research also covers inflammation, immunology and rare diseases. William H. Lewis is its chief executive officer.

ARIKAYCE is an inhaled medicine for a lung infection caused by Mycobacterium avium complex, or MAC. In the United States, it is used with other antibacterial medicines for adults with limited or no alternative treatment options whose infection has not responded to prior treatment. It is also approved for specified patients in Europe and Japan. Patients inhale ARIKAYCE through the Lamira nebulizer, which delivers the medicine to the lungs.

BRINSUPRI is a once-daily tablet for non-cystic fibrosis bronchiectasis, a chronic lung disease in which the airways become permanently widened and patients experience recurring infections and inflammation. It is approved in the United States for patients aged 12 and older and in the European Union for patients in that age group with two or more exacerbations in the prior 12 months.

Insmed is also developing TPIP, an inhaled candidate for several lung and pulmonary hypertension conditions; brensocatib for an inflammatory skin disease; and gene therapies for Duchenne muscular dystrophy and amyotrophic lateral sclerosis. These candidates require further development and regulatory approval before they can be marketed for those uses.

How it makes money

Insmed earns product revenue from sales of ARIKAYCE and BRINSUPRI. It reports one segment, and its product revenue is recorded after allowances for items such as customer credits, prompt-payment discounts, service fees, government rebates and chargebacks. Revenue therefore reflects amounts net of those adjustments, rather than simply a list price multiplied by prescriptions.

Both medicines are intended for continuing treatment: BRINSUPRI is taken orally once daily, while ARIKAYCE is inhaled once daily as part of a combination antibacterial regimen. Product revenue depends on patients receiving treatment, physician prescribing, insurance coverage and reimbursement. Insmed also faces negotiations over pricing and reimbursement in international markets.

Revenue: FY2025 product revenue was $606.4 million; in Q2 2026, BRINSUPRI produced $309.2 million and ARIKAYCE produced $116.3 million.

ARIKAYCE generated $433.8 million in FY2025, or 71.5% of revenue. BRINSUPRI generated $172.7 million, or 28.5%, following its US launch during the year. The reportable segment’s revenue rose 66.7% in FY2025 from FY2024, reflecting the BRINSUPRI launch and increased ARIKAYCE sales.

Insmed expects full-year 2026 BRINSUPRI revenue of $1.25 to $1.4 billion and ARIKAYCE revenue of $450 to $470 million. It does not expect a meaningful BRINSUPRI revenue contribution from Japan in 2026, although it expects a regulatory decision there in the second half of the year. The company has also financed operations through equity, debt and revenue-interest arrangements; those are financing sources rather than product sales.

Customers and how it sells

Insmed’s medicines are prescribed for patients with specific respiratory diseases. Physicians decide whether to prescribe them, while patient access can depend on government programs and other third-party insurers. In the United States, Medicare, Medicaid and independent third-party payors reimburse dispensers of pharmaceutical products. Patients’ willingness and ability to pay out-of-pocket costs also affect access.

Customer concentration is disclosed without identifying the customers. Customer A accounted for 31.0% of FY2025 revenue. Customer B accounted for 26.0% of FY2025 revenue. Customer C accounted for 17.0% of FY2025 revenue. Customer D accounted for 12.0% of FY2025 revenue.

US revenue was $453.0 million in FY2025, while international revenue was $153.5 million. ARIKAYCE is approved in the United States, Europe and Japan. BRINSUPRI is approved in the United States and the European Union, with different eligibility conditions in the two markets.

Access after approval varies by country. ARIKAYCE is reimbursed nationally in several European markets, including France and the United Kingdom. In Italy, Insmed has not reached an acceptable national reimbursement price, but the product remains available for physicians to prescribe with funding agreed locally. For BRINSUPRI, the company is preparing for a potential Japanese launch, subject to approval and an acceptable price.

Suppliers and costs

Insmed uses third parties to manufacture products and support clinical development. PARI develops and manufactures Lamira, the nebulizer designed to deliver ARIKAYCE. Insmed licensed brensocatib, the active drug in BRINSUPRI, from AstraZeneca. The available disclosures do not identify either as a sole-source supplier.

Cost of product revenue includes manufacturing, packaging, freight, overhead and royalty expenses. BRINSUPRI has lower manufacturing costs than ARIKAYCE. Insmed expects cost of product revenue to benefit as it sells BRINSUPRI inventory whose costs were expensed before approval.

Research and development spending covers staff, clinical studies, manufacturing of investigational medicines and delivery devices, and payments for licensed rights or acquired assets. Contract manufacturers make product candidates for studies, while contract research organizations conduct and manage trials. Selling and administrative expenses include commercial staff, field sales, legal services and other corporate functions.

In FY2025, cost of product revenue excluding intangible amortization was $122.9 million, and research and development expense was $771.1 million. Insmed expects research and development expense to increase in 2026 as it funds clinical trials and other research. It also expects to incur significant commercialization costs and continuing operating losses.

Competitive position

Insmed competes in respiratory medicine and develops candidates in other areas where pharmaceutical companies, biotechnology companies, research institutions and other organizations are active. No company is named as a competitor in the supplied disclosures. The company expects potential competitors to offer medicines that are more effective, safer, less expensive or easier to use, and it may also face generic competition.

Insmed is not aware of another approved inhaled therapy specifically indicated for refractory nontuberculous mycobacterial lung infections in North America, Europe or Japan. ARIKAYCE is included in international treatment guidelines as part of a combination regimen for eligible patients. The FDA granted it a total of 12 years of exclusivity for its approved indication.

For bronchiectasis, Insmed is not aware of an approved treatment other than BRINSUPRI in the United States and European Union. Other entities are conducting clinical studies, including studies of drugs that inhibit the same enzyme as brensocatib. Pulmonary arterial hypertension, one of TPIP’s proposed uses, already has marketed treatments, including other formulations of treprostinil.

Our reading: ARIKAYCE’s approved indication, guideline position and delivery technology provide protection in its current niche, but other recommended treatments and potential generics limit that protection. Our reading: BRINSUPRI’s existing approval gives it an initial position in bronchiectasis, while competing clinical programs could challenge it. Our reading: TPIP’s competitive position remains unproven because it is still in clinical development in markets with established treatments.

Growth opportunities

Insmed’s growth plans include expanding BRINSUPRI prescribing, reaching patients in additional markets and seeking a broader ARIKAYCE label. The company estimates that 500,000 patients have diagnosed bronchiectasis in the United States, 600,000 in the European 5 and 150,000 in Japan. It is also working to improve diagnosis among patients who have bronchiectasis alongside COPD or asthma.

BRINSUPRI added approximately 7,000 new patients in Q2 2026. Insmed expects approximately 7,000 new patient starts per quarter for the remaining quarters of 2026. It expects a Japanese regulatory decision in the second half of 2026, with launch dependent on approval and pricing.

For ARIKAYCE, the company has submitted a US application for use in newly diagnosed patients with MAC lung disease and intends to submit an application in Japan in the second half of 2026. The current US approval is limited to a refractory population. Insmed sees potential launches for a broader indication in 2027, subject to regulatory decisions.

The pipeline provides additional potential indications. Insmed is enrolling patients in Phase 3 TPIP studies for pulmonary hypertension associated with interstitial lung disease and for pulmonary arterial hypertension. It plans further Phase 3 studies in progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. Insmed is also testing brensocatib for hidradenitis suppurativa and advancing earlier-stage rare-disease programs. The FDA cleared INS1033, another DPP1 inhibitor, to enter clinical testing; rheumatoid arthritis is its first planned indication.

Structural risks

• Product dependence and adoption: Insmed’s prospects depend on ARIKAYCE and BRINSUPRI. Their success relies on physicians’ willingness to prescribe, patients’ willingness to use and tolerate them, and sufficient insurance coverage and reimbursement.
• Safety and continued approval: ARIKAYCE carries a US boxed warning associated with an increased risk of respiratory adverse reactions. New safety information or failure to meet ongoing regulatory obligations could lead to labeling changes, restrictions or withdrawal of approval.
• Clinical development: Pharmaceutical development is costly and uncertain. Insmed must conduct appropriate studies and obtain approvals before marketing candidates or expanding indications. ARIKAYCE’s accelerated US approval also requires a post-marketing confirmatory clinical trial.
• Competition: Other developers are studying treatments for bronchiectasis, and established products are already marketed for some conditions targeted by Insmed’s pipeline. Competing or generic products could reduce its commercial opportunity.
• Funding and spending: Insmed expects continuing operating losses as it funds clinical programs and commercialization. It may raise additional capital for future development or other business activities, although it believes it is funded through expected cash flow positivity in 2027.
• Manufacturing and compliance: Products and their third-party manufacturers must meet manufacturing, quality and other regulatory requirements. Failures can result in shortages, recalls, enforcement actions or restrictions on operations.

Bottom line

Our reading

Our reading: Insmed is a respiratory-drug business whose revenue is shifting with the BRINSUPRI launch, while ARIKAYCE remains an established contributor. Its longer-term business depends on sustaining prescribing and reimbursement, expanding into other markets and converting clinical programs into approved products. Development costs, safety obligations and competition remain material exposures.